Meghan Fitzgerald is Director at Roivant Sciences Ltd. (ROIV). They have made 6 open-market trades across 2 companies since 2020, most recently 2026-09-16.
CIK 0001349297
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $160K since 2020, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| THC | 17,580 | $5.1M |
| CAH | 16,760 | $4.4M |
| ROIV | 41,162 | $1.6M |
| VION | 555,000 | — |
| Total | $11.1M |
Shares reported on the most recent Form 4, priced at the 2026-09-18 close. 1 holding could not be priced and is excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ROIV | SELL · 10b5-1 | 2026-09-15 | 2026-09-17 | $39.74 | $203K | -9.1% | -13.6% | — |
| ROIV | SELL · 10b5-1 | 2026-09-08 | 2026-09-10 | $39.90 | $798K | -7.4% | -16.2% | — |
| ROIV | SELL | 2026-06-30 | 2026-07-02 | $34.90 | $349K | -0.2% | -4.6% | +4.6% |
| ROIV | SELL | 2026-03-26 | 2026-03-30 | $27.45 | $1.9M | +5.5% | +2.8% | +29.9% |
| THC | SELL | 2024-08-06 | 2024-08-08 | $146.34 | $2.9M | +3.7% | +2.4% | +7.1% |
| THC | SELL | 2021-09-16 | 2021-09-20 | $72.70 | $884K | -8.6% | -9.7% | +0.3% |
| THC | SELL | 2021-05-24 | 2021-05-26 | $63.57 | $782K | +3.5% | +6.9% | +11.1% |
| THC | BUY | 2020-03-17 | 2020-03-18 | $13.02 | $160K | +46.9% | +106.5% | +105.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.